IBRX vs. SRPT, PCVX, QGEN, ROIV, RVMD, LEGN, LNTH, TGTX, BBIO, and AXSM
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), Lantheus (LNTH), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.
ImmunityBio vs.
Sarepta Therapeutics (NASDAQ:SRPT) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Sarepta Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics has a net margin of 7.43% compared to ImmunityBio's net margin of -8,016.83%. Sarepta Therapeutics' return on equity of 11.00% beat ImmunityBio's return on equity.
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by insiders. Comparatively, 83.4% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sarepta Therapeutics presently has a consensus target price of $167.41, suggesting a potential upside of 127.43%. ImmunityBio has a consensus target price of $12.19, suggesting a potential upside of 344.80%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Sarepta Therapeutics.
In the previous week, Sarepta Therapeutics had 38 more articles in the media than ImmunityBio. MarketBeat recorded 40 mentions for Sarepta Therapeutics and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.67 beat Sarepta Therapeutics' score of -0.10 indicating that ImmunityBio is being referred to more favorably in the news media.
Sarepta Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Sarepta Therapeutics received 1453 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 75.09% of users gave Sarepta Therapeutics an outperform vote while only 41.67% of users gave ImmunityBio an outperform vote.
Summary
Sarepta Therapeutics beats ImmunityBio on 12 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
This page (NASDAQ:IBRX) was last updated on 3/25/2025 by MarketBeat.com Staff
